Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ocular Therapeutix, Inc. logo — company profile

Ocular Therapeutix, Inc.

Founded 2006 United States Bedford, United States 325 employees Post Ipo Equity Total: $711.51M Biotechnology, Health Care +1

General Information

Company Name Ocular Therapeutix, Inc.
Founded Year 2006
Location United States Bedford, United States +1
Founders / Decision Makers
Team member
Employees 325
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post Ipo Equity
Social

Get notified when Ocular Therapeutix, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company that has been advancing groundbreaking solutions in the field since its founding in 2006. Located in the United States, the company focuses on innovating treatments for retinal diseases, a pressing need in the biotechnology and health care industries.

Central to Ocular Therapeutix's strategy is its leading investigational candidate, AXPAXLI™ (also known as OTX-TKI), which uses the proprietary ELUTYX™ technology. This axitinib hydrogel, administered via intravitreal injection, is currently in Phase 3 clinical trials targeting wet age-related macular degeneration (wet AMD), and showing promise for conditions like non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).

The company's innovative potential was endorsed by a substantial $325.00M post-IPO equity investment on 22 February 2024. Notable investors include Deep Track Capital, Logos Capital, Perceptive Advisors, and Venrock Healthcare Capital Partners, among others, signifying robust confidence in its strategic direction and innovative prospects.

Taxonomy: biopharmaceutical, ophthalmic, drug delivery, hydrogel-based, FDA-approved, clinical programs, intravitreal implant, eye therapies, innovative treatments, ophthalmic surgery, ocular diseases, specialty sales, intracameral injection, pharmaceutical industry, eye care

Services & Products

Development of therapies for retinal diseases
Clinical trials for eye treatments
Research and development of pharmaceuticals

Target Customers

Patients with retinal diseases Healthcare providers specializing in ophthalmology Biopharmaceutical investors

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 9
Investor Investor Investor Investor Investor Investor
•••• •••• 		22 Feb 2024
Post-IPO Equity •••••• - 13 Dec 2023
Post-IPO Equity •••••• - 20 May 2020
Post-IPO Debt •••••• - 01 Mar 2019
Post-IPO Equity •••••• - 24 Jan 2018

View All 12 Funding Rounds

Ocular Therapeutix, Inc. Alternatives & Competitors

View All Alternatives
Ocular Therapeutix, Inc. vs
Lakeshore Optical
Lakeshore Optical United States

Comprehensive care for your eyes with expert exams and precision treatments.

2 employees
Fashion, Health Care
Compare Ocular Therapeutix, Inc. vs Lakeshore Optical
Ocular Therapeutix, Inc. vs
Elman Retina Group
Elman Retina Group

Providing expert care for your retinal health needs, from macular degeneration to retinal tears. Con...

Health Care
Ocular Therapeutix, Inc. vs
Northern Eye Care Associates
Northern Eye Care Associates

Comprehensive eye care services and products for all your vision needs.

5 employees
Fashion, Health Care
Also compare with: Ocular Therapeutix, Inc. vs Inland Valley Retina Inland Valley Retina Ocular Therapeutix, Inc. vs Retina Associates of Cleveland, Inc. Retina Associates of Cleveland, Inc. View all alternatives

FAQ About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational c...
Ocular Therapeutix, Inc. was founded in 2006.
Ocular Therapeutix, Inc. is headquartered in Bedford, United States.
Ocular Therapeutix, Inc. operates in the following industries: Biotechnology, Health Care, Medical Devices.
Ocular Therapeutix, Inc. has approximately 325 employees.
Ocular Therapeutix, Inc. has completed 12 funding rounds, raising a total of $711.51M. The latest funding stage is Post Ipo Equity.
Ocular Therapeutix, Inc. offers: Development of therapies for retinal diseases, Clinical trials for eye treatments, Research and development of pharmaceuticals.
Top alternatives and competitors to Ocular Therapeutix, Inc. include Lakeshore Optical, Elman Retina Group, Northern Eye Care Associates, Inland Valley Retina, Retina Associates of Cleveland, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ocular Therapeutix, Inc. and Lakeshore Optical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ocular Therapeutix, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes